Complement Factor B Modulation for Selective Complement Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Inappropriate complement activation contributes to various diseases, including atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), IgA nephropathy (IgAN), systemic lupus erythematosus (SLE), diabetic nephropathy, membranous nephropathy, polycystic kidney disease, age-related macular degeneration, thrombotic microangiopathy, myasthenia gravis, ischemia, reperfusion injury, and rheumatoid arthritis (RA), leading to tissue damage such as ocular and kidney damage.

Innovation Solution

Development of compounds and compositions that modulate the expression or activity of Complement Factor B (CFB) to reduce CFB mRNA and protein levels, thereby inhibiting complement pathway dysregulation and associated tissue damage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If complement pathway is activated to fight infection, then immune defense is improved, but tissue damage occurs due to inappropriate activation

Engineering Contradiction:

Improveimmune defenseVSAvoidtissue damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses C3 neurotoxin as an intermediary substance that specifically binds to and neutralizes C3 convertase, preventing inappropriate complement activation and subsequent tissue damage while preserving the immune system's ability to fight infection

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If CFB expression is inhibited to treat complement-related diseases, then tissue damage is reduced, but complement pathway function may be compromised

Engineering Contradiction:

Improvetissue damageVSAvoidcomplement pathway function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent extracts and targets the specific problematic component (C3 convertase containing CFB) for inhibition, rather than suppressing the entire complement pathway, thereby treating tissue damage while preserving overall complement function

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

C3 neurotoxin acts as a selective intermediary that inhibits CFB-containing C3 convertase specifically, allowing treatment of complement-related diseases without completely disabling the complement pathway

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12595477B2Complement Factor B-modulating compositions and methods of use thereof

Publication Date: 2026.04.07 ADARX PHARMACEUTICALS INC

AI summary

Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.